Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22821788 | 0.94 | EGFR (0.95) | EGFR | |
| SCHEMBL22821812 | 0.94 | EGFR (0.81) | EGFR | |
| SCHEMBL22025903 | 0.93 | EGFR (1.00) | EGFR | |
| SCHEMBL22821851 | 0.93 | EGFR (1.00) | EGFR | |
| SCHEMBL26053608 | 0.92 | EGFR (0.90) | EGFR | |
| SCHEMBL22821790 | 0.91 | EGFR (0.87) | EGFR | |
| SCHEMBL22821707 | 0.91 | EGFR (0.89) | EGFR | |
| SCHEMBL22821921 | 0.91 | EGFR (0.88) | EGFR | |
| SCHEMBL22595663 | 0.91 | EGFR (1.00) | EGFR | |
| SCHEMBL25340594 | 0.91 | EGFR (0.88) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| CN-112513029-A | Nitrogen-containing aryl phosphorus oxide derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020253862-A1 | NITROGEN-CONTAINING ARYL PHOSPHORUS OXIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.